{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:14:03Z","timestamp":1794276843170,"version":"4.9.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>No comprehensive collection of routine therapeutic drug monitoring data for antipsychotic drugs has been published.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this compilation, data on 12 antipsychotics are presented. The drugs included are amisulpride (n = 506), aripiprazole (n = 1610), clozapine (n = 1189), flupentixol (n = 215), haloperidol (n = 390), olanzapine (n = 10,268), perphenazine (n = 1065), quetiapine (n = 5853), risperidone (n = 3255), sertindole (n = 111), ziprasidone (n = 1235), and zuclopenthixol (n = 691). Because only one sample per patient is included, the number of patients equals the number of samples. For each drug, median serum concentrations as well as that of the 10th and 90th percentiles are given for a range of daily doses. Comparisons are made between males and females, between patients younger than 65 years and 65 years and older, and between those treated with a low and a high dose of each drug. The concentration-to-dose (C\/D) ratio is the primary variable used in these comparisons. Coefficients of variation (CVs) for the serum concentrations of each drug within and between subjects are presented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In general, the C\/D ratios were higher in females than in males, higher in those 65 years and older than in younger subjects, and lower in those treated with higher doses than in those treated with lower doses. CVs between individuals were larger than within subjects, and the CVs were highest for the drugs with short elimination half-lives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>For each antipsychotic drug, the results presented can serve as a reference tool for pharmacokinetic interpretation of the individual patient's serum drug level. The compiled serum concentrations and the C\/D ratios can support the physician's decision when individualizing dosing and determining treatment strategies for a specific patient.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000585","type":"journal-article","created":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T23:12:26Z","timestamp":1546038746000},"page":"348-356","source":"Crossref","is-referenced-by-count":61,"title":["A Compilation of Serum Concentrations of 12 Antipsychotic Drugs in a Therapeutic Drug Monitoring Setting"],"prefix":"10.1097","volume":"41","author":[{"given":"Anna K.","family":"J\u00f6nsson","sequence":"first","affiliation":[{"name":"Department of Forensic Chemistry and Genetics, National Board of Forensic Medicine, Link\u00f6ping, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olav","family":"Spigset","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, St. Olav University Hospital, Trondheim;"},{"name":"Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margareta","family":"Reis","sequence":"additional","affiliation":[{"name":"Division of Drug Research, Department of Medical and Health Sciences, Link\u00f6ping University, Link\u00f6ping; and"},{"name":"Division of Laboratory Medicine, Department of Clinical Chemistry and Pharmacology, Sk\u00e5ne University Hospital, Lund, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1503\/cmaj.1041064","article-title":"Modern antipsychotic drugs: a critical overview","volume":"172","author":"Gardner","year":"2005","journal-title":"CMAJ."},{"key":"R2-20230814","first-page":"431","article-title":"Conventional versus novel antipsychotics: changing concepts and clinical implications","volume":"24","author":"Remington","year":"1999","journal-title":"J Psychiatry Neurosci."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/schbul\/sbn023","article-title":"Secondary effects of antipsychotics: women at greater risk than men","volume":"35","author":"Seeman","year":"2009","journal-title":"Schizophr Bull."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/YCO.0000000000000243","article-title":"Issues related to sex differences in antipsychotic treatment","volume":"29","author":"Crawford","year":"2016","journal-title":"Curr Opin Psychiatry."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2165\/00002018-200629070-00004","article-title":"Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?","volume":"29","author":"Aichhorn","year":"2006","journal-title":"Drug Saf."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/FTD.0b013e3182708ec5.","article-title":"Therapeutic drug monitoring of common antipsychotics","volume":"34","author":"Patteet","year":"2012","journal-title":"Ther Drug Monit."},{"key":"R8-20230814","first-page":"443","article-title":"Compliance with SSRI medication during 6 months of treatment for major depression: an evaluation by determination of repeated serum drug concentrations","volume":"82","author":"Reis","year":"2004","journal-title":"J Affect Disord."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/jat\/31.5.254","article-title":"Reference concentrations of antidepressants. A compilation of postmortem and therapeutic levels","volume":"31","author":"Reis","year":"2007","journal-title":"J Anal Toxicol."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/FTD.0b013e31819114ea","article-title":"Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database","volume":"31","author":"Reis","year":"2009","journal-title":"Ther Drug Monit."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.4088\/JCP.v68n1011","article-title":"Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service","volume":"68","author":"Castberg","year":"2007","journal-title":"J Clin Psychiatry."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1055\/s-2007-977715","article-title":"Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service","volume":"40","author":"Castberg","year":"2007","journal-title":"Pharmacopsychiatry."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/JCP.0b013e3181b2fced","article-title":"Does level of care, sex, age, or choice of drug influence adherence to treatment with antipsychotics?","volume":"29","author":"Castberg","year":"2009","journal-title":"J Clin Psychopharmacol."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.forsciint.2016.05.002","article-title":"Antipsychotics\u2014postmortem fatal and non-fatal reference concentrations","volume":"266","author":"S\u00f6derberg","year":"2016","journal-title":"Forensic Sci Int."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"143","DOI":"10.17772\/gp\/2002","article-title":"Gender-specific implications for pharmacology in childbearing age and in postmenopausal women","volume":"86","author":"Bartkowiak-Wieczorek","year":"2015","journal-title":"Ginekologia polska."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-200241050-00002","article-title":"How important are gender differences in pharmacokinetics?","volume":"41","author":"Meibohm","year":"2002","journal-title":"Clin Pharmacokinet."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/JCP.0b013e318221b408","article-title":"Plasma olanzapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1999-2009","volume":"31","author":"Patel","year":"2011","journal-title":"J Clin Psychopharmacol."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4088\/JCP.v60n0108","article-title":"Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics","volume":"60","author":"Lane","year":"1999","journal-title":"J Clin Psychiatry."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/0269881105053306","article-title":"Influence of age and gender on risperidone plasma concentrations","volume":"19","author":"Aichhorn","year":"2005","journal-title":"J Psychopharmacol."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/acps.12794","article-title":"Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine","volume":"136","author":"Castberg","year":"2017","journal-title":"Acta Psychiatr Scand."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hup.2256","article-title":"Plasma amisulpride in relation to prescribed dose, clozapine augmentation, and other factors: data from a therapeutic drug monitoring service, 2002-2010","volume":"27","author":"Bowskill","year":"2012","journal-title":"Hum Psychopharmacol."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/01.ftd.0000249944.42859.bf","article-title":"Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients","volume":"28","author":"Molden","year":"2006","journal-title":"Ther Drug Monit."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/FTD.0b013e318178e18d","article-title":"Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia","volume":"30","author":"Bachmann","year":"2008","journal-title":"Ther Drug Monit."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/FTD.0b013e31821160c4","article-title":"Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients","volume":"33","author":"Bakken","year":"2011","journal-title":"Ther Drug Monit."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/bcpt.12614","article-title":"Impact of ageing on serum concentrations of risperidone and its active metabolite in patients with known CYP2D6 genotype","volume":"119","author":"Molden","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/FTD.0000000000000457","article-title":"Serum concentrations of paliperidone after administration of the long-acting injectable formulation","volume":"39","author":"Helland","year":"2017","journal-title":"Ther Drug Monit."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201906000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T18:35:22Z","timestamp":1692038122000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201906000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000585","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}